Scarica l'app Stockscreener
1.72
0.58%
-0.01
Pre-mercato:
1.66
-0.06
-3.49%
Inmed Pharmaceuticals Inc Borsa (INM) Ultime notizie
InMed-Mentari migraine merger backed by $290 million financing reshapes company strategy (INM) - MSN
InMed Pharmaceuticals Q3 2025 Earnings: Continued Losses as Stock DeclinesTrough Earnings Signal - Newser
InMed Pharmaceuticals Q3 2025 Earnings: Net Loss Widens Amid Pipeline FocusFree Market Insights - Newser
InMed Pharmaceuticals Shares Surge Following Mentari Merger Announcement - HarianBasis.co
ADAR1-managed funds add 468,551 InMed (INM) shares in open-market buys - Stock Titan
InMed (INM) major holder ADAR1 reports 331,449 indirect shares on Form 3 - Stock Titan
InMed Pharmaceuticals Merges with Mentari Therapeutics to Target Migraine Prevention - HarianBasis.co
INM Stock Alert: What to Know as InMed, Mentari Announce Merger - Barchart.com
/C O R R E C T I O N -- InMed Pharmaceuticals/ - PR Newswire
Mentari Therapeutics: $290 Million Private Placement Supports Merger With InMed Pharmaceuticals To Advance Migraine Prevention Therapies - Pulse 2.0
InMed Pharmaceuticals (INM) Stock Doubled on Mentari Merger — Why the Rally Is Already Being Tested - TechStock²
Penny stock InMed Pharmaceuticals merger deal targets migraine pipeline - MSN
Mentari lists via InMed merger, takes $290m for migraine pipeline - The Pharma Letter
InMed Pharmaceuticals (INM) Soars 170% on Merger with Mentari Th - GuruFocus
Law firm investigates InMed Pharmaceuticals' board over possible unfair sale to Mentari Therapeutics - Pluang
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM) - GlobeNewswire
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM) - GlobeNewswire Inc.
Mentari, InMed Merge In Deal Backed By $290M Funding - Law360
InMed Pharmaceuticals, Inc. (INM) Stock: Climbs on $290M Private Placement and Migraine Pipeline Deal - parameter.io
InMed Pharmaceuticals and Mentari Therapeutics Announce $290M Merger to Advance Migraine Prevention Therapies - Minichart
InMed Pharmaceuticals Lowers Armistice Preferred Investment Option Exercise Price from $16.60 to $0.80 - Minichart
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
InMed amends warrant terms, cuts exercise price to $0.80 - Investing.com UK
InMed Soars 100% on $290M Migraine Deal - TechStock²
InMed Pharmaceuticals (INM) Merges with Mentari Therapeutics for Migraine Treatment Development - GuruFocus
Trending Stocks Today | Amesite Surges 150.6% - Moomoo
InMed amends warrant terms, cuts exercise price to $0.80 By Investing.com - Investing.com South Africa
A migraine drugmaker heads to the public markets through reverse merger - BioPharma Dive
INM Stock Alert: Halper Sadeh LLC is Investigating Whether InMed Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders - The Joplin Globe
User - The Chronicle-Journal
InMed-Mentari Migraine Merger Backed by $290 Million Financing Reshapes Company Strategy (INM) - Yahoo Finance
InMed (INM) agrees merger with Mentari; Mentari investors to hold ~98.5% - Stock Titan
Mentari Therapeutics to go public via InMed (NASDAQ: INM) merger - Stock Titan
InMed Pharmaceuticals stock surges on Mentari merger deal By Investing.com - Investing.com Nigeria
Penny Stock InMed Pharmaceuticals Merger Deal Targets Migraine Pipeline - Benzinga
INM Stock Jumps On Heavy Volume As Traders Scan Charts - StocksToTrade
InMed Pharmaceuticals stock surges on Mentari merger deal - Investing.com UK
InMed Pharmaceuticals Announces Merger with Mentari Therapeutics - Intellectia AI
INM Stock Slides As Traders Weigh Cash Runway And Steep Losses - timothysykes.com
Hehehe! Cut off the ticker symbol! And Diluted cost! Hehehe! - Moomoo
InMed and Mentari announce all-stock merger deal (INM:NASDAQ) - Seeking Alpha
InMed Pharmaceuticals InMed shareholders are expected to own approximately 1.51% of combined company - marketscreener.com
Inmed Pharmaceuticals Inmed Shareholders Are Expected To Own Approximately 1.51% Of Combined Company - TradingView
According to the latest disclosure, following the completion of the relevant transaction, the pro forma equity value of the merged company, InMed Pharmaceuticals Inc, is expected to reach approximately $421.4 million. - Bitget
Press Release: InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies - Moomoo
InMed Pharmaceuticals Lowers Exercise Price on Preferred Options - TipRanks
InMed (INM) slashes Armistice option exercise price from $16.60 to $0.80 - Stock Titan
Armistice can buy 278,761 InMed shares at $0.80 after deal - Stock Titan
InMed Highlights INM-901 Alzheimer’s Data in Q3 Update - TipRanks
TradingKey - TradingKey
Pharmaniaga Bhd. (PHARMA) - Minichart
InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update - Moomoo
1.92%
4.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):